Evidence map›Paper›PMID 29307797›Full record

ArticleExperimental and molecular pathology2018

Alcoholic hepatitis versus non-alcoholic steatohepatitis: Levels of expression of some proteins involved in tumorigenesis.

Luan Nguyen, Maryam Masouminia, Alejandro Mendoza, Sara Samadzadeh, Brittany Tillman, Timothy Morgan, Barbara French, Samuel French

Open access · greenAbstract read
In one paragraph

Article in Experimental and molecular pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Luan NguyenHarbor-UCLA Medical Center, Torrance, CA, United States. Electronic address: lnguyen23289@yahoo.com.
Maryam MasouminiaHarbor-UCLA Medical Center, Torrance, CA, United States.
Alejandro MendozaHarbor-UCLA Medical Center, Torrance, CA, United States.
Sara SamadzadehHarbor-UCLA Medical Center, Torrance, CA, United States.
Brittany TillmanHarbor-UCLA Medical Center, Torrance, CA, United States.
Timothy MorganVA Medical Center, Long Beach, CA, United States.
Barbara FrenchHarbor-UCLA Medical Center, Torrance, CA, United States.
Samuel FrenchHarbor-UCLA Medical Center, Torrance, CA, United States.
Harbor–UCLA Medical Center · USLong Beach Medical Center · US

Funding

ALCOHOLIC HEPATITIS PATHOGENESIS AS DETERMINED FROM HUMAN LIVER TISSUE ANALYSISU01AA021898 · NIAAA · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI FRENCH, SAMUEL WILLIAM · 2013 to 2017
$1.0M
NIAAA NIH HHS U01 AA021898
6 · The paper itself

Abstract

Non-alcoholic steatohepatitis (NASH) is commonly associated with obesity, type 2 diabetes, and/or hypertriglyceridemia, while alcoholic steatohepatitis (ASH) is associated with alcohol abuse. Both NASH and ASH patients can develop cirrhosis and hepatocellular carcinoma (HCC) if left untreated. However, the rate of tumorigenesis in NASH and ASH appears to be different. Individuals with NASH progress to HCC at a rate of 0.5% annually (Lindenmeyer and McCullough, 2018), when individuals with ASH progress to HCC at a rate of 3-10% annually (Schwartz and Reinus, 2012). Thus, the objective of our study is to determine if there are differences in NASH versus ASH in the levels of different proteins expressed involved in cancer development. The method used was measuring the proteins expressed in liver biopsied sections from NASH and ASH patients using immunohistochemical staining with fluorescent antibodies and then quantitating the fluorescence intensity morphometrically. The 20 proteins tested are parts of the Ingenuity Canonical Pathway of Molecular Mechanisms of Cancer and include: RAP2B, NAIP, FYN, PAK6, SUV39H1, GNAI1, BAX, E2F3, CKDN2B, BAK1, BCL2, DIABLO, RASGRF2, GNA15, PIK3CB, BRCA1, MAP2K1, BIRC3, CDK2, and ATM. In ASH, the proteins that showed upregulated levels of expression were SUV39H1, E2F3, BCL2, BAK1, BIRC3, and GNAI1. In NASH, the proteins that showed upregulated levels of expression were BAK1 and GNAI1 and the protein that showed downregulated level of expression was BCL2. Additionally, levels of expression for SUV39H1, E2F3, BCL2, BAK1, BIRC3, and GNAI1 were significant upregulated in ASH compared to NASH. These results showed significant differences in ASH compared to normal liver, and significant differences in ASH compared to NASH. Thus, we conclude that there are more proteins involved in tumorigenesis in ASH compared to NASH and in ASH compared to normal liver, which is consistent with the known tumor development rate in ASH and NASH.

Indexed as

BiopsyCarcinogenesisCarcinoma, HepatocellularDiabetes Mellitus, Type 2Hepatitis, AlcoholicHumansImmunohistochemistryLiver NeoplasmsNon-alcoholic Fatty Liver DiseaseObesityAlcoholic hepatitisHepatocellular carcinoma (HCC)Pre-cancer gene expressionTumorigenesis

Identifiers

PMID29307797
PMCPMC5800980
OpenAlexW2781600281

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.